MaxCyte, Inc.
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; Ex…
Medical - Devices
US, Rockville [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about MaxCyte, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2015 | - | -0.030 | - | 9 | - | -3 | - | -5 | - | -5 | - | 8 |
| 2016 | - | 0.000 | - | 12 | - | 0 | - | -7 | - | -7 | - | 11 |
| 2017 | - | -0.209 | - | 14 | - | -21 | - | -8 | - | -8 | - | 12 |
| 2018 | - | -0.180 | - | 16 | - | -18 | - | -9 | - | -10 | - | 15 |
| 2019 | - | -0.248 | - | 19 | - | -25 | - | -11 | - | -11 | - | 17 |
| 2020 | - | -0.195 | - | 26 | - | -20 | - | -15 | - | -15 | - | 24 |
| 2021 | - | -0.216 | - | 33 | - | -22 | - | -19 | - | -20 | - | 30 |
| 2022 | -0.2200 | -0.256 | 33 | 44 | -20 | -26 | -16 | -25 | -18 | -27 | 31 | 40 |
| 2023 | -0.1900 | -0.395 | 44 | 39 | -19 | -40 | -20 | -22 | -27 | -23 | 44 | 35 |
| 2024 | -0.3700 | -0.414 | 41 | 37 | -37 | -42 | -44 | -21 | -48 | -22 | 57 | 34 |
| 2025 | - | -0.377 | - | 46 | - | -38 | - | -26 | - | -28 | - | 42 |
| 2026 | - | 2.F11X/td> | - | 2.F11X/td> | - | 2.F11X/td> | - | 2.F111/td> | - | 2.F111 | - | 2.F111 |
| 2027 | - | 1.F12X/td> | - | 1.F12X/td> | - | 1.F12X/td> | - | 1.F121/td> | - | 1.F121 | - | 1.F121 |
| 2028 | - | 0.F13X/td> | - | 0.F13X/td> | - | 0.F13X/td> | - | 0.F131/td> | - | 0.F131 | - | 0.F131 |